- Home
- AZ vs ALT Comparison
AZ vs ALT Comparison
Compare AZ & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZ
- ALT
- Stock Information
- Founded
- AZ 2018
- ALT 1997
- Country
- AZ Canada
- ALT United States
- Employees
- AZ N/A
- ALT N/A
- Industry
- AZ Industrial Machinery/Components
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- AZ Industrials
- ALT Health Care
- Exchange
- AZ Nasdaq
- ALT Nasdaq
- Market Cap
- AZ 319.5M
- ALT 348.6M
- IPO Year
- AZ N/A
- ALT N/A
- Fundamental
- Price
- AZ $5.38
- ALT $4.69
- Analyst Decision
- AZ Strong Buy
- ALT Strong Buy
- Analyst Count
- AZ 1
- ALT 7
- Target Price
- AZ $20.00
- ALT $16.33
- AVG Volume (30 Days)
- AZ 359.0K
- ALT 3.0M
- Earning Date
- AZ 11-13-2025
- ALT 11-06-2025
- Dividend Yield
- AZ N/A
- ALT N/A
- EPS Growth
- AZ N/A
- ALT N/A
- EPS
- AZ N/A
- ALT N/A
- Revenue
- AZ $6,962,000.00
- ALT $20,000.00
- Revenue This Year
- AZ $1,343,857.60
- ALT N/A
- Revenue Next Year
- AZ N/A
- ALT N/A
- P/E Ratio
- AZ N/A
- ALT N/A
- Revenue Growth
- AZ 20.51
- ALT N/A
- 52 Week Low
- AZ $5.00
- ALT $2.90
- 52 Week High
- AZ $12.36
- ALT $10.88
- Technical
- Relative Strength Index (RSI)
- AZ 32.28
- ALT 69.65
- Support Level
- AZ $5.02
- ALT $3.95
- Resistance Level
- AZ $5.49
- ALT $4.23
- Average True Range (ATR)
- AZ 0.46
- ALT 0.26
- MACD
- AZ -0.06
- ALT 0.05
- Stochastic Oscillator
- AZ 16.21
- ALT 97.64
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.